Berupipam (INNTooltip International Nonproprietary Name; developmental code name NNC 22-0010) is a selective dopamine D1 receptor antagonist of the benzazepine group which was under development for the treatment of psychotic disorders but was never marketed. It reached phase 1 clinical trials prior to the discontinuation of its development.
Berupipam and closely related dopamine D1 receptor antagonists were reported to have been generally well-tolerated in clinical trials, but side effects included restlessness, drowsiness, other central nervous system-related symptoms, and orthostatic hypotension.
Berupipam, in radiolabeled form, has been studied for use in positron emission tomography (PET) imaging. The drug was first described in the scientific literature by 1994.
See also
- Ecopipam (SCH-39166)
- NNC 01-0687 (ADX-10061)
- Odapipam (NNC 01-0756)
- SCH-23390
References
